JP2017523209A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523209A5 JP2017523209A5 JP2017505836A JP2017505836A JP2017523209A5 JP 2017523209 A5 JP2017523209 A5 JP 2017523209A5 JP 2017505836 A JP2017505836 A JP 2017505836A JP 2017505836 A JP2017505836 A JP 2017505836A JP 2017523209 A5 JP2017523209 A5 JP 2017523209A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally substituted
- pharmaceutically acceptable
- acceptable salt
- membered
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 cyano, hydroxy Chemical group 0.000 claims 38
- 150000003839 salts Chemical class 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 19
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 13
- 125000001072 heteroaryl group Chemical group 0.000 claims 13
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 11
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 9
- 229910052757 nitrogen Inorganic materials 0.000 claims 8
- 125000004043 oxo group Chemical group O=* 0.000 claims 8
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims 6
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 6
- 125000000041 C6-C10 aryl group Chemical group 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000001153 fluoro group Chemical group F* 0.000 claims 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002883 imidazolyl group Chemical group 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 3
- 125000003373 pyrazinyl group Chemical group 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000002098 pyridazinyl group Chemical group 0.000 claims 3
- 125000004076 pyridyl group Chemical group 0.000 claims 3
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 3
- 125000001425 triazolyl group Chemical group 0.000 claims 3
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000002047 benzodioxolyl group Chemical group O1OC(C2=C1C=CC=C2)* 0.000 claims 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims 2
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 125000001544 thienyl group Chemical group 0.000 claims 2
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- YDADFGXXCHDXFC-UHFFFAOYSA-N C(#N)C1=CC=C(C=N1)C1=C(N=C2N1N=CC=C2)C(=O)NC1CC1 Chemical compound C(#N)C1=CC=C(C=N1)C1=C(N=C2N1N=CC=C2)C(=O)NC1CC1 YDADFGXXCHDXFC-UHFFFAOYSA-N 0.000 claims 1
- KZFDLYSKEWBCTB-UHFFFAOYSA-N C1(CC1)NC(=O)C=1N=C2N(N=CC=C2)C=1C=1C=CC=2N(C=1)N=CN=2 Chemical compound C1(CC1)NC(=O)C=1N=C2N(N=CC=C2)C=1C=1C=CC=2N(C=1)N=CN=2 KZFDLYSKEWBCTB-UHFFFAOYSA-N 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- IJGCWHSMOTWWLO-UHFFFAOYSA-N ClC1=CC(=C(C=C1F)C1=C(N=C2N1N=CC=C2)C(=O)NC1CC1)F Chemical compound ClC1=CC(=C(C=C1F)C1=C(N=C2N1N=CC=C2)C(=O)NC1CC1)F IJGCWHSMOTWWLO-UHFFFAOYSA-N 0.000 claims 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- OUXBYUBGWJQGHZ-UHFFFAOYSA-N N1(CCC1)C(=O)C=1N=C2N(N=CC=C2)C=1C1=CC=C(C=C1)Cl Chemical compound N1(CCC1)C(=O)C=1N=C2N(N=CC=C2)C=1C1=CC=C(C=C1)Cl OUXBYUBGWJQGHZ-UHFFFAOYSA-N 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 208000002205 allergic conjunctivitis Diseases 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000024998 atopic conjunctivitis Diseases 0.000 claims 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 125000003016 chromanyl group Chemical group O1C(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 125000005433 dihydrobenzodioxinyl group Chemical group O1C(COC2=C1C=CC=C2)* 0.000 claims 1
- 125000000723 dihydrobenzofuranyl group Chemical group O1C(CC2=C1C=CC=C2)* 0.000 claims 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 claims 1
- 125000005057 dihydrothienyl group Chemical group S1C(CC=C1)* 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims 1
- 125000001041 indolyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 125000003384 isochromanyl group Chemical group C1(OCCC2=CC=CC=C12)* 0.000 claims 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 1
- 125000004621 quinuclidinyl group Chemical group N12C(CC(CC1)CC2)* 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000003507 tetrahydrothiofenyl group Chemical group 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462033684P | 2014-08-06 | 2014-08-06 | |
| US62/033,684 | 2014-08-06 | ||
| US201562157129P | 2015-05-05 | 2015-05-05 | |
| US62/157,129 | 2015-05-05 | ||
| PCT/IB2015/055597 WO2016020786A1 (en) | 2014-08-06 | 2015-07-23 | Imidazopyridazine compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019065718A Division JP2019163256A (ja) | 2014-08-06 | 2019-03-29 | イミダゾピリダジン化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523209A JP2017523209A (ja) | 2017-08-17 |
| JP2017523209A5 true JP2017523209A5 (enExample) | 2018-08-30 |
| JP6506833B2 JP6506833B2 (ja) | 2019-04-24 |
Family
ID=54065405
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017505836A Active JP6506833B2 (ja) | 2014-08-06 | 2015-07-23 | イミダゾピリダジン化合物 |
| JP2019065718A Pending JP2019163256A (ja) | 2014-08-06 | 2019-03-29 | イミダゾピリダジン化合物 |
| JP2021037945A Active JP7074903B2 (ja) | 2014-08-06 | 2021-03-10 | イミダゾピリダジン化合物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019065718A Pending JP2019163256A (ja) | 2014-08-06 | 2019-03-29 | イミダゾピリダジン化合物 |
| JP2021037945A Active JP7074903B2 (ja) | 2014-08-06 | 2021-03-10 | イミダゾピリダジン化合物 |
Country Status (32)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| AU2015298378B2 (en) | 2014-08-06 | 2018-08-02 | Pfizer Inc. | Imidazopyridazine compounds |
| CN108699080B (zh) | 2016-02-23 | 2021-05-14 | 辉瑞公司 | 6,7-二氢-5H-吡唑并[5,1-b][1,3]噁嗪-2-甲酰胺化合物 |
| MA47106A (fr) | 2016-12-21 | 2019-10-30 | Amgen Inc | Formulations d'anticorps anti-tnf alpha |
| EP3678660A4 (en) | 2017-09-07 | 2021-07-14 | Board of Regents of the University of Nebraska | TRPC5 INHIBITORS AND THEIR METHODS OF USE |
| WO2019197632A1 (en) * | 2018-04-13 | 2019-10-17 | Healx Limited | Treatment of fragile x syndrome |
| WO2020087031A1 (en) | 2018-10-26 | 2020-04-30 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| KR20210151823A (ko) * | 2019-03-15 | 2021-12-14 | 스카이호크 테라퓨틱스, 인코포레이티드 | 비정상적인 스플라이싱을 보정하기 위한 조성물 및 방법 |
| US12370192B2 (en) | 2019-09-16 | 2025-07-29 | Takeda Pharmaceutical Company Limited | Azole-fused pyridazin-3(2H)-one derivatives |
| KR20220086607A (ko) * | 2019-10-21 | 2022-06-23 | 에스케이바이오팜 주식회사 | 발달 장애의 예방, 경감 또는 치료를 위한 이미다조피리미딘 또는 이미다조트리아진 화합물의 용도 |
| CN112194660B (zh) * | 2020-10-20 | 2021-12-03 | 常州大学 | 一种pde2抑制剂苯基吡唑并嘧啶类化合物及其制备方法 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5814651A (en) | 1992-12-02 | 1998-09-29 | Pfizer Inc. | Catechol diethers as selective PDEIV inhibitors |
| US5750349A (en) | 1993-01-25 | 1998-05-12 | Takeda Chemical Industries Ltd. | Antibodies to β-amyloids or their derivatives and use thereof |
| JPH08295667A (ja) * | 1995-04-27 | 1996-11-12 | Takeda Chem Ind Ltd | 複素環化合物、その製造法および剤 |
| DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
| US8173127B2 (en) | 1997-04-09 | 2012-05-08 | Intellect Neurosciences, Inc. | Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof |
| AU743827B2 (en) | 1997-04-09 | 2002-02-07 | Intellect Neurosciences, Inc. | Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof |
| GB9722520D0 (en) | 1997-10-24 | 1997-12-24 | Pfizer Ltd | Compounds |
| US6905686B1 (en) | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
| EP1181296A1 (en) | 1999-06-03 | 2002-02-27 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| EP1196408B1 (en) | 1999-06-28 | 2004-09-15 | Janssen Pharmaceutica N.V. | Respiratory syncytial virus replication inhibitors |
| EP1244668B1 (en) | 2000-01-07 | 2006-04-05 | Universitaire Instelling Antwerpen | Purine derivatives, process for their preparation and use thereof |
| SK288711B6 (sk) | 2000-02-24 | 2019-11-05 | Univ Washington | Humanizovaná protilátka, jej fragment a ich použitie, polynukleová kyselina, expresný vektor, bunka a farmaceutický prostriedok |
| CA2407573C (en) | 2000-04-27 | 2011-09-13 | Yamanouchi Pharmaceutical Co. Ltd. | Imidazopyridine derivatives |
| DE10045112A1 (de) | 2000-09-11 | 2002-03-21 | Merck Patent Gmbh | Verwendung von Indolderivaten zur Behandlung von Erkrankungen des zentralen Nervensystems |
| CA2427661C (en) | 2000-11-03 | 2013-05-28 | Proteotech, Inc. | Methods of isolating amyloid-inhibiting compounds and use of compounds isolated from uncaria tomentosa and related plants |
| GB0115181D0 (en) | 2001-06-20 | 2001-08-15 | Glaxo Group Ltd | Novel use |
| WO2003000697A1 (en) | 2001-06-22 | 2003-01-03 | Takeda Chemical Industries, Ltd. | Furoisoquinoline derivative, process for producing the same, and use |
| US6919353B2 (en) | 2001-06-27 | 2005-07-19 | Merck Frosst Canada & Co. | Substituted 8-arylquinolune PDE4 inhibitors |
| EP1405844A4 (en) | 2001-06-29 | 2006-09-20 | Nikken Chemicals Co Ltd | CYCLOALKENONDERIVAT |
| WO2003008396A1 (en) | 2001-07-16 | 2003-01-30 | Nikken Chemicals Co., Ltd. | Optically active oxazine derivative |
| WO2003008392A1 (de) | 2001-07-18 | 2003-01-30 | Merck Patent Gmbh | 4-(benzyliden-amino)-3-(methylsulfanyl) -4h-(1, 2, 4) triazin-5-on derivate mit pde -iv hemmender und tnf-antagonistischer wirkung zur behandlung von herzkrankheiten und allergien |
| WO2003008373A1 (de) | 2001-07-19 | 2003-01-30 | Merck Patent Gmbh | Tyrosinhydrazide |
| FR2827599A1 (fr) | 2001-07-20 | 2003-01-24 | Neuro3D | Composes derives de quinoleine et quinoxaline,preparation et utilisations |
| GB0118373D0 (en) | 2001-07-27 | 2001-09-19 | Glaxo Group Ltd | Novel therapeutic method |
| TWI221838B (en) | 2001-08-09 | 2004-10-11 | Tanabe Seiyaku Co | Pyrazinoisoquinoline compound or naphthalene compound |
| EP1285922A1 (en) | 2001-08-13 | 2003-02-26 | Warner-Lambert Company | 1-Alkyl or 1-cycloalkyltriazolo[4,3-a]quinazolin-5-ones as phosphodiesterase inhibitors |
| FR2828693B1 (fr) | 2001-08-14 | 2004-06-18 | Exonhit Therapeutics Sa | Nouvelle cible moleculaire de la neurotoxicite |
| WO2003015789A2 (en) | 2001-08-15 | 2003-02-27 | Leo Pharma A/S | A pharmaceutical composition for dermal application |
| EP1423120A4 (en) | 2001-08-15 | 2005-12-28 | Icos Corp | 2H-PHTALAZINE-1-ONES AND METHODS OF USE THEREOF |
| EP1432444A4 (en) | 2001-08-17 | 2005-11-02 | Lilly Co Eli | ANTI-BETA ANTIBODIES |
| JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyl inhibitors Ariel phosphodiesterase-4 |
| GB0122031D0 (en) | 2001-09-12 | 2001-10-31 | Pfizer Ltd | Use of pde4 inhibitors in a dry powder inhaler |
| PL205927B1 (pl) | 2001-09-19 | 2010-06-30 | Nycomed Gmbh | Kompozycja farmaceutyczna zawierająca inhibitor PDE - roflumilast i antagonistę receptora leukotrienowego - montelukast, sposób wytwarzania tej kompozycji, produkt farmaceutyczny i zestaw zawierający te związki oraz zastosowanie kompozycji i produktu farmaceutycznego |
| WO2003024489A2 (en) | 2001-09-19 | 2003-03-27 | Altana Pharma Ag | Combination of a nsaid and a pde-4 inhibitor |
| WO2003035650A1 (en) | 2001-09-25 | 2003-05-01 | Takeda Chemical Industries, Ltd. | Entry inhibitor |
| EA007429B1 (ru) | 2001-10-02 | 2006-10-27 | Фармация Энд Апджон Компани | Азабициклические замещённые конденсированные гетероарильные соединения |
| GB0123951D0 (en) | 2001-10-05 | 2001-11-28 | Glaxo Group Ltd | Therapies for treating respiratory diseases |
| DE10150517A1 (de) | 2001-10-12 | 2003-04-17 | Merck Patent Gmbh | Verwendung von Phosphodiesterase IV-Inhibitoren |
| AU2002335015B8 (en) | 2001-10-16 | 2006-11-30 | Memory Pharmaceuticals Corporation | 4-(4-alkoxy-3-hydroxyphenyl)-2-pyrrolidone derivatives as pde-4 inhibitors for the treatment of neurological syndromes |
| US7241890B2 (en) | 2001-10-30 | 2007-07-10 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
| EP1463509A1 (en) | 2001-10-31 | 2004-10-06 | MERCK PATENT GmbH | Type 4 phosphodiesterase inhibitors and uses thereof |
| WO2003037900A2 (en) | 2001-11-01 | 2003-05-08 | Icagen, Inc. | Pyrazolopyrimidines |
| US20030195205A1 (en) | 2001-11-02 | 2003-10-16 | Pfizer Inc. | PDE9 inhibitors for treating cardiovascular disorders |
| CA2465746C (en) | 2001-11-05 | 2011-09-06 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Hydrazono-malonitriles |
| MY130622A (en) | 2001-11-05 | 2007-07-31 | Novartis Ag | Naphthyridine derivatives, their preparation and their use as phosphodiesterase isoenzyme 4 (pde4) inhibitors |
| US20030092706A1 (en) | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
| IS7221A (is) | 2001-11-15 | 2004-04-15 | Memory Pharmaceuticals Corporation | Hringlaga adenosínmónófosfat fosfódíesterasa 4D7 ísóform og aðferðir til notkunar þeirra |
| FR2832711B1 (fr) | 2001-11-26 | 2004-01-30 | Warner Lambert Co | Derives de triazolo [4,3-a] pyrido [2,3-d] pyrimidin-5-ones, compositions les contenant, procede de preparation et utilisation |
| US20050101000A1 (en) | 2002-12-11 | 2005-05-12 | Isis Pharmaceuticals Inc. | Modulation of phosphodiesterase 4B expression |
| DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
| DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
| JP2006519762A (ja) | 2002-10-09 | 2006-08-31 | ライナット ニューロサイエンス コーポレイション | アミロイドβペプチド及びその組成物に対する抗体を使用して、アルツハイマー病を治療する方法 |
| WO2004042390A2 (en) | 2002-11-08 | 2004-05-21 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human phosphodiesterase 4b (pde4b) |
| US7550470B2 (en) | 2002-12-11 | 2009-06-23 | Merck & Co. Inc. | Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors |
| ATE455547T1 (de) | 2003-04-11 | 2010-02-15 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1, 2,4-triazolen |
| EP1615697A2 (en) | 2003-04-11 | 2006-01-18 | Novo Nordisk A/S | New pyrazolo[1,5-a] pyrimidine derivatives and pharmaceutical use thereof |
| US20040220186A1 (en) | 2003-04-30 | 2004-11-04 | Pfizer Inc. | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| CA2528975A1 (en) | 2003-06-10 | 2004-12-16 | Pfizer Inc. | Therapeutic combinations comprising pde inhibitors and vasopressin receptor antagonists for the treatment of dysmenorrhoea |
| MXPA05013770A (es) | 2003-06-19 | 2006-03-08 | Pfizer Prod Inc | Antagonista de neuroquinina 1. |
| US20060148805A1 (en) | 2003-07-01 | 2006-07-06 | Meng Hsin Chen | Opthalmic compositions for treating ocular hypertension |
| FR2857966A1 (fr) | 2003-07-24 | 2005-01-28 | Aventis Pharma Sa | Produits aryl-heteroaromatiques, compositions les contenant et utilisation |
| US20050020587A1 (en) | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| US20070031416A1 (en) | 2003-09-09 | 2007-02-08 | Takeda Pharmaceutical Company Limited | Use of antibody |
| GB0322722D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| GB0322726D0 (en) | 2003-09-27 | 2003-10-29 | Glaxo Group Ltd | Compounds |
| JP2007506440A (ja) | 2003-09-29 | 2007-03-22 | トピジェン・ファルマスーティック・インコーポレーテッド | 炎症性症状を含む疾患を治療するための、オリゴヌクレオチド組成物および方法 |
| GB0327319D0 (en) | 2003-11-24 | 2003-12-24 | Pfizer Ltd | Novel pharmaceuticals |
| US20050137234A1 (en) | 2003-12-19 | 2005-06-23 | Syrrx, Inc. | Histone deacetylase inhibitors |
| WO2005080361A1 (en) | 2004-02-02 | 2005-09-01 | Pfizer Products Inc. | Histamine-3 receptor modulators |
| CA2565965A1 (en) | 2004-05-06 | 2006-07-27 | Plexxikon, Inc. | Pde4b inhibitors and uses therefor |
| US7456164B2 (en) | 2004-05-07 | 2008-11-25 | Pfizer, Inc | 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands |
| EP1595881A1 (en) | 2004-05-12 | 2005-11-16 | Pfizer Limited | Tetrahydronaphthyridine derivates useful as histamine H3 receptor ligands |
| BRPI0513959A (pt) | 2004-07-30 | 2008-05-20 | Rinat Neuroscience Corp | anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos |
| US7605168B2 (en) | 2004-09-03 | 2009-10-20 | Plexxikon, Inc. | PDE4B inhibitors |
| GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| BRPI0515477A (pt) | 2004-09-20 | 2008-07-22 | Xenon Pharmaceuticals Inc | derivados heterocìclicos bicìclicos e o uso dos mesmos como inibidores de estaroil-coa-desaturase (scd) |
| KR20070057965A (ko) | 2004-09-21 | 2007-06-07 | 신타 파마슈티칼스 코프. | 염증 및 면역 관련 용도를 위한 화합물 |
| GB0423356D0 (en) | 2004-10-21 | 2004-11-24 | Merck Sharp & Dohme | Therapeutic agents |
| DE102004054634A1 (de) | 2004-11-12 | 2006-05-18 | Schwarz Pharma Ag | Azaindolcarboxamide |
| EP1827493A4 (en) | 2004-12-22 | 2009-09-30 | Univ St Louis | USE OF ANTI-ABETA ANTIBODIES FOR THE TREATMENT OF BRAIN TRAUMA |
| WO2006088246A1 (ja) | 2005-02-18 | 2006-08-24 | Takeda Pharmaceutical Company Limited | Ｇｐｒ３４受容体機能調節剤 |
| GB0503955D0 (en) | 2005-02-25 | 2005-04-06 | Glaxo Group Ltd | Novel compounds |
| UY29504A1 (es) | 2005-04-29 | 2006-10-31 | Rinat Neuroscience Corp | Anticuerpos dirigidos contra el péptido amiloide beta y métodos que utilizan los mismos. |
| EP1881985B1 (en) | 2005-05-12 | 2010-12-29 | Pfizer, Inc. | Anhydrous crystalline forms of n-ý1-(2-ethoxyethyl)-5-(n-ethyl-n-methylamino)-7-(4-methylpyridin-2-yl-amino)-1h-pyrazolo[4,3-d]pyrimidine-3-carbonyl¨methanesulfonamide |
| WO2006126083A1 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3 , 4-b] pyrazinone compounds as pde-5 inhibitors |
| WO2006126082A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridine [3,4-b] pyrazinones as pde-5 inhibitors |
| WO2006126081A2 (en) | 2005-05-24 | 2006-11-30 | Pharmacia & Upjohn Company Llc | Pyridino [2 , 3-b] pyrazinones as pde-5 inhibitors |
| ES2354569T3 (es) | 2005-06-22 | 2011-03-16 | Pfizer Products Inc. | Antagonistas del receptor de histamina-3. |
| WO2007013673A1 (en) * | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
| US8158673B2 (en) | 2005-10-27 | 2012-04-17 | Pfizer Inc. | Histamine-3 receptor antagonists |
| EP1945639A1 (en) | 2005-11-04 | 2008-07-23 | Pfizer Limited | Tetrahydronaphthyridine derivative |
| WO2007063385A2 (en) | 2005-12-01 | 2007-06-07 | Pfizer Products Inc. | Spirocyclic amine histamine-3 receptor antagonists |
| WO2007069053A1 (en) | 2005-12-14 | 2007-06-21 | Pfizer Products Inc. | Benzimidazole antagonists of the h-3 receptor |
| WO2007088450A2 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Chromane antagonist of the h-3 receptor |
| WO2007088462A1 (en) | 2006-02-01 | 2007-08-09 | Pfizer Products Inc. | Spirochromane antagonists of the h-3 receptor |
| WO2007099423A1 (en) | 2006-03-02 | 2007-09-07 | Pfizer Products Inc. | 1-pyrrolidine indane derivatives as histamine-3 receptor antagonists |
| US20090163482A1 (en) | 2006-03-13 | 2009-06-25 | Mchardy Stanton Furst | Tetralines antagonists of the h-3 receptor |
| GB0605462D0 (en) | 2006-03-17 | 2006-04-26 | Glaxo Group Ltd | Novel compounds |
| WO2007122466A1 (en) | 2006-04-21 | 2007-11-01 | Pfizer Products Inc. | Pyridine[3,4-b]pyrazinones |
| WO2007138431A2 (en) | 2006-05-30 | 2007-12-06 | Pfizer Products Inc. | Azabicyclic ether histamine-3 antagonists |
| US20080090834A1 (en) | 2006-07-06 | 2008-04-17 | Pfizer Inc | Selective azole pde10a inhibitor compounds |
| US8138205B2 (en) | 2006-07-07 | 2012-03-20 | Kalypsys, Inc. | Heteroarylalkoxy-substituted quinolone inhibitors of PDE4 |
| JP5280357B2 (ja) | 2006-07-07 | 2013-09-04 | スティーブン・ピー・ガベック | Ｐｄｅ４の二環式ヘテロアリール阻害剤 |
| DK2054416T3 (da) | 2006-08-04 | 2011-04-04 | Merz Pharma Gmbh & Co Kgaa | Substituerede pyrazolopyrimidiner, en fremgangsmåde til deres frembringelse samt deres anvendelse som medicin |
| EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
| WO2008033739A2 (en) * | 2006-09-12 | 2008-03-20 | Neurogen Corporation | Benzimidazole carboxamide derivatives |
| US20090275586A1 (en) | 2006-10-06 | 2009-11-05 | Kalypsys, Inc. | Heterocyclic inhibitors of pde4 |
| WO2008045663A2 (en) | 2006-10-06 | 2008-04-17 | Kalypsys, Inc. | Aryl-substituted heterocyclic pde4 inhibitors as antiinflammatory agents |
| US20080102475A1 (en) | 2006-10-13 | 2008-05-01 | Zhengyan Kan | Alternatively spliced isoform of phosphodiesterase 4B (PDE4B) |
| CL2007002994A1 (es) | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| WO2008056176A1 (en) | 2006-11-10 | 2008-05-15 | Scottish Biomedical Limited | Pyrazolopyrimidines as phosphodiesterase inhibitors |
| KR101108109B1 (ko) | 2007-01-22 | 2012-02-06 | 화이자 프로덕츠 인코포레이티드 | 치료 화합물의 토실레이트 염 및 이의 약학 조성물 |
| UA99729C2 (en) | 2007-08-10 | 2012-09-25 | Х. Луннбек А/С | Heteroaryl amide analogues |
| TW200922569A (en) | 2007-08-10 | 2009-06-01 | Genelabs Tech Inc | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| US8431608B2 (en) | 2007-08-17 | 2013-04-30 | Icagen Inc. | Heterocycles as potassium channel modulators |
| EP2085398A1 (en) | 2008-02-01 | 2009-08-05 | Merz Pharma GmbH & Co. KGaA | Pyrazolopyrimidines, a process for their preparation and their use as medicine |
| WO2009108551A2 (en) | 2008-02-25 | 2009-09-03 | H. Lundbeck A/S | Heteroaryl amide analogues |
| GB2461702A (en) | 2008-07-08 | 2010-01-13 | Dyson Technology Ltd | Hand drying apparatus |
| US9643922B2 (en) | 2008-08-18 | 2017-05-09 | Yale University | MIF modulators |
| ES2710701T3 (es) | 2008-09-24 | 2019-04-26 | Basf Se | Compuestos de pirazol para el control de plagas de invertebrados |
| WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| PT2408446T (pt) | 2009-03-20 | 2019-12-18 | Hg&H Pharmaceuticals Pty Ltd | Utilização de composições farmacêuticas contendo mesembrenona |
| AU2010311511B2 (en) * | 2009-10-30 | 2014-07-17 | Janssen Pharmaceutica Nv | Imidazo[1,2-b]pyridazine derivatives and their use as PDE10 inhibitors |
| AU2010323209A1 (en) | 2009-11-25 | 2012-06-14 | Merz Pharma Gmbh & Co. Kgaa | Crystalline forms of substituted pyrazolopyrimidines |
| AR079451A1 (es) | 2009-12-18 | 2012-01-25 | Nycomed Gmbh | Compuestos 3,4,4a,10b-tetrahidro-1h-tiopirano[4,3-c]isoquinolina |
| US8759359B2 (en) | 2009-12-18 | 2014-06-24 | Incyte Corporation | Substituted heteroaryl fused derivatives as PI3K inhibitors |
| EP2549874A4 (en) | 2010-03-23 | 2013-10-02 | High Point Pharmaceuticals Llc | SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS |
| CA2796826A1 (en) | 2010-05-10 | 2011-11-17 | Gilead Sciences, Inc. | Bifunctional quinoline derivatives |
| AR081377A1 (es) | 2010-05-10 | 2012-08-29 | Gilead Sciences Inc | Compuestos de pirazolopiridina bifuncionales |
| WO2012067822A1 (en) | 2010-11-16 | 2012-05-24 | Abbott Laboratories | Pyrazolo [1, 5 -a] pyrimidin potassium channel modulators |
| US9096605B2 (en) | 2011-08-24 | 2015-08-04 | Glaxosmithkline Llc | Pyrazolopyrimidine derivatives as PI3 kinase inhibitors |
| EA201591360A1 (ru) | 2013-02-19 | 2016-03-31 | Пфайзер Инк. | Азабензимидазолы в качестве ингибиторов изозимов фдэ4 для лечения цнс и других расстройств |
| WO2014200882A1 (en) * | 2013-06-11 | 2014-12-18 | Janssen Pharmaceutica Nv | PDE10a INHIBITORS FOR THE TREATMENT OF TYPE II DIABETES |
| GB201321734D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic Agents |
| EP3172210B1 (en) | 2014-07-24 | 2020-01-15 | Pfizer Inc | Pyrazolopyrimidine compounds |
| AU2015298378B2 (en) | 2014-08-06 | 2018-08-02 | Pfizer Inc. | Imidazopyridazine compounds |
-
2015
- 2015-07-23 AU AU2015298378A patent/AU2015298378B2/en not_active Ceased
- 2015-07-23 CN CN201580053973.4A patent/CN106795165B/zh not_active Expired - Fee Related
- 2015-07-23 AP AP2017009744A patent/AP2017009744A0/en unknown
- 2015-07-23 MX MX2017001565A patent/MX376283B/es active IP Right Grant
- 2015-07-23 CU CUP2017000007A patent/CU20170007A7/es unknown
- 2015-07-23 BR BR112017001334A patent/BR112017001334A2/pt not_active IP Right Cessation
- 2015-07-23 DK DK15760263.2T patent/DK3177624T3/da active
- 2015-07-23 WO PCT/IB2015/055597 patent/WO2016020786A1/en not_active Ceased
- 2015-07-23 ES ES15760263T patent/ES2733502T3/es active Active
- 2015-07-23 EP EP15760263.2A patent/EP3177624B1/en active Active
- 2015-07-23 HU HUE15760263A patent/HUE044040T2/hu unknown
- 2015-07-23 PL PL15760263T patent/PL3177624T3/pl unknown
- 2015-07-23 SG SG11201700243YA patent/SG11201700243YA/en unknown
- 2015-07-23 TN TN2017000031A patent/TN2017000031A1/en unknown
- 2015-07-23 KR KR1020177005702A patent/KR102061952B1/ko active Active
- 2015-07-23 MD MDA20170011A patent/MD20170011A2/ro not_active Application Discontinuation
- 2015-07-23 GE GEAP201514410A patent/GEP20196950B/en unknown
- 2015-07-23 PT PT15760263T patent/PT3177624T/pt unknown
- 2015-07-23 EA EA201700042A patent/EA031201B1/ru not_active IP Right Cessation
- 2015-07-23 PE PE2017000077A patent/PE20170295A1/es not_active Application Discontinuation
- 2015-07-23 JP JP2017505836A patent/JP6506833B2/ja active Active
- 2015-07-23 CR CR20170035A patent/CR20170035A/es unknown
- 2015-07-31 CA CA2899294A patent/CA2899294C/en not_active Expired - Fee Related
- 2015-08-04 US US14/817,606 patent/US9598421B2/en active Active
- 2015-08-05 UY UY0001036257A patent/UY36257A/es not_active Application Discontinuation
- 2015-08-05 TW TW104125458A patent/TWI577681B/zh not_active IP Right Cessation
- 2015-08-05 TW TW105142733A patent/TWI629276B/zh not_active IP Right Cessation
-
2017
- 2017-01-13 PH PH12017500095A patent/PH12017500095A1/en unknown
- 2017-02-02 CO CONC2017/0000980A patent/CO2017000980A2/es unknown
- 2017-02-03 DO DO2017000034A patent/DOP2017000034A/es unknown
- 2017-02-03 EC ECIEPI20177336A patent/ECSP17007336A/es unknown
- 2017-02-06 IL IL250478A patent/IL250478B/en active IP Right Grant
- 2017-02-07 US US15/426,423 patent/US10077269B2/en active Active
- 2017-02-09 SV SV2017005381A patent/SV2017005381A/es unknown
-
2018
- 2018-08-07 US US16/056,968 patent/US20180346475A1/en not_active Abandoned
- 2018-10-26 AU AU2018253590A patent/AU2018253590A1/en not_active Abandoned
-
2019
- 2019-03-29 JP JP2019065718A patent/JP2019163256A/ja active Pending
- 2019-04-16 IL IL266108A patent/IL266108A/en active IP Right Grant
- 2019-06-27 US US16/455,020 patent/US10669279B2/en active Active
-
2021
- 2021-03-10 JP JP2021037945A patent/JP7074903B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523209A5 (enExample) | ||
| AU2012313094B2 (en) | Pyrazole carboxamides as janus kinase inhibitors | |
| JP2014512331A5 (enExample) | ||
| HRP20050682A2 (en) | Pyrazolopyridine derivatives | |
| ES2794779T3 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo como inhibidores de JAK | |
| JP6232429B2 (ja) | ＲＯＲγＴ阻害剤としての３−シクロヘキセニルおよびシクロヘキシル置換インドールおよびインダゾール化合物およびそれらの使用 | |
| JP2014516074A5 (enExample) | ||
| HRP20191364T1 (hr) | Sik-inhibitori tipa heteroarila | |
| JP2016519156A5 (enExample) | ||
| JP2019519583A5 (enExample) | ||
| JP2016507581A5 (enExample) | ||
| JP2011503150A5 (enExample) | ||
| JP2013536235A5 (enExample) | ||
| JP2016523911A5 (enExample) | ||
| WO2014026330A1 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| EP2683710A1 (en) | Soluble guanylate cyclase activators | |
| JP2017512779A5 (enExample) | ||
| JP2015501847A5 (enExample) | ||
| JP5208111B2 (ja) | Ｐ３８ｍａｐキナーゼ阻害剤としての１，７−ナフチリジン誘導体 | |
| JP2012502890A5 (enExample) | ||
| JP2017525737A5 (enExample) | ||
| CA2685597C (en) | Pyrazolo-pyridinone and pyrazolo-pyrazinone compounds as p38 modulators, process for their preparation, and their pharmaceutical use | |
| HRP20180973T1 (hr) | Supstituirani tiazolski ili oksazolski antagonisti p2x7 receptora | |
| AU2014234906A1 (en) | Cycloalkyl nitrile pyrazolo pyridones as Janus kinase inhibitors | |
| JP2019505558A5 (enExample) |